Kimyrsa Injection, Powder, Lyophilized, For Solution
Product Images NDC 70842-225

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Kimyrsa (NDC 70842-225). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Melinta Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Kimyrsa 01)

Chemical structure diagram of oritavancin diphosphate, the active ingredient in Kimyrsa 1200 mg/40mL injection, powder, lyophilized, for intravenous solution by Melinta Therapeutics, LLC.*

FDA Label Image

Principal Display Panel (1,200 mg Vial Carton)

Kimyrsa (oritavancin) for injection 1,200 mg per vial packaging label. The label states it is for intravenous infusion only, single-dose vial, must be reconstituted and diluted to 250 mL. The vial contains oritavancin and excipients for pH adjustment. Marketed by Melinta Therapeutics, LLC, Lincolnshire, IL. The label includes dosage recommendations, storage conditions, and multiple barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.